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Abstract: Background: Diabetes aggravates brain injury after cerebral
ischemia/reperfusion (I/R). Objective: To investigate whether limb I/R
causes cerebral injury in a rat diabetes model and whether glycogen
synthase kinase-3b (GSK-3b) is involved. Methods: Male adult
Sprague-Dawley rats were assigned into streptozotocin-induced diabe-
tes (n 5 30; blood glucose $16.7 mmol/L) or control (n 5 20) groups,
further subdivided into diabetes I/R (3-hour femoral artery/vein clamp-
ing), diabetes-I/R + TDZD-8 (I/R plus GSK-3b inhibitor), diabetes-
sham, control-sham and control-I/R groups (n 5 10 each). Cortical
and hippocampal morphology (hematoxylin/eosin); hippocampal CA1
apoptosis (TUNEL assay); cleaved caspase-3 (apoptosis), and Iba1 (mi-
croglial activation) protein expression (immunohistochemistry);
phosphorylated/total GSK-3b and nuclear factor-kB (NF-kB) protein
levels (Western blotting); and serum and brain tissue tumor necrosis
factor (TNF)-a levels (enzyme-linked immunosorbent assay) were ana-
lyzed. Results: The diabetes-I/R group showed greater cortical and
hippocampal injury, apoptosis, cleaved caspase-3 expression and Iba1
expression than the control-I/R group; TDZD-8 reduced injury/
apoptosis and cleaved caspase-3/Iba1 expressions. The diabetes-I/R
group had lower p-GSK-3b and p-NF-kBp65 expression than the
control-I/R group (P , 0.05); TDZD-8 increased p-GSK-3b expression
but decreased p-NF-kBp65 expression (P , 0.05). The diabetes-I/R
group showed higher elevation of serum and brain tissue TNF-a than
the control-I/R group (P , 0.05); TDZD-8 reduced TNF-a production.
Conclusions: Diabetes exacerbates limb I/R-induced cerebral damage
and activates NF-kB and GSK-3b.
Key Indexing Terms: Glycogen synthase kinase-3b (GSK-3b); Dia-
betes mellitus; Ischemia/reperfusion; Cerebral injury; Nuclear factor-kB
(NF-kB); Tumor necrosis factor-a (TNF-a). [Am J Med Sci 2015;350
(3):204–211.]
D iabetes is a systemic disease that can cause chronic andprogressive destruction of many organs, including the eyes,
kidneys, cardiovascular system and peripheral nervous system.
More recently, increasing attention has been paid to the central
nervous system complications of diabetes,1 which include hippo-
campal damage,2 impairments in learning and memory3,4 and an
enhanced risk of age-related neurodegeneration.5 A variety of
factors have been implicated in the cognitive deﬁcits associated
with diabetes.1 Interestingly, diabetes has also been reported to
aggravate brain injury after cerebral ischemia/reperfusion (I/R),
which is characterized by neuronal cell apoptosis.6
Lower limb ischemia is a common scenario encountered
in clinic practice that can have a variety of underlying causes
(including peripheral blood vessel embolism or damage, severe
injury to the lower limb or inappropriate use of a tourniquet).
Although restoration of the blood supply is the premise for
rescuing the ischemic limb, the reperfusion can itself induce I/R
injury, a metabolic disorder associated with structural destruc-
tion of the ischemic tissues. Clinical and animal studies have
shown that severe I/R injury not only damages the limb skeletal
muscle but can also induce systemic inﬂammatory response
syndrome and even remote multiple organ dysfunction syn-
drome7 affecting the lungs, heart, liver and intestine. The brain
is also sensitive to I/R injury, and there is evidence in an animal
model that hindlimb I/R can cause a systemic inﬂammatory
response that results in microglial cell activation and neuronal
apoptosis.8
Glycogen synthase kinase-3b (GSK-3b), one of the rate-
limiting enzymes in glycogen synthesis, is a serine/threonine
protein kinase that is highly expressed in the central nervous
system, especially in the hippocampus and neocortex. GSK-3b
has almost 50 substrates, including plasmosin and nuclear tran-
scription factors and can modulate transduction in multiple cell
signaling pathways closely related to diabetes, I/R, inﬂamma-
tion, neurodegenerative disease and cancer.9 GSK-3b has been
shown to have critical functions in regulating the balance
between cell survival and apoptosis.10 An important feature of
GSK-3b is that it has intracellular catalytic activity in the
absence of any stimuli, and that its kinase activity can be
enhanced by phosphorylation at Thr-216. Under normal condi-
tions, the activity of GSK-3b is downregulated by cell survival
signals, including insulin and growth factors, which act through
the phosphoinositide 3-kinase (PI3K)/Akt pathway. Hence,
excessive activation or inadequate suppression of GSK-3b
can induce apoptosis.
GSK-3b has been implicated in the cognitive changes
observed in models of diabetes and indeed has been proposed to
be a molecular link between insulin, diabetes and Alzheimer’s
disease.11 In streptozotocin (STZ)- or pancreatectomy-induced rat
models of diabetes, the activity of hippocampal GSK-3b is signif-
icantly higher than that in normal rats,12 whereas learning and
memory functions are decreased.13 Furthermore, treatment with
a GSK-3b inhibitor has been reported to improve learning and
memory in rats with diabetes.14 Inﬂammation induced by I/R injury
can aggravate the destruction of neurons and GSK-3b may be
relevant to this process, as it exerts critical functions in modulating
the balance between proinﬂammatory and anti-inﬂammatory cyto-
kine production in the central nervous system.15 For example,
GSK-3b, nuclear factor-kB (NF-kB) and tumor necrosis factor-a
(TNF-a) have been suggested to play a role in inﬂammation and
apoptosis of neurons and microglia.16,17 Furthermore, inhibiting
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GSK-3b in microglial cells can block the inﬂammatory response
stimulated by activation of NF-kB and production of TNF-a and
enhance the levels of anti-inﬂammatory cytokines.18
Many patients with diabetes will require surgery and
anesthesia, and limb I/R injury is not rare. The authors have
observed that patients with diabetes have a lower tolerance to
surgery and anesthesia and a poorer prognosis than patients
without diabetes. Insulin resistance has been shown to exacer-
bate cortical injury during ischemia,19 and importantly, GSK-
3b, NF-kB and TNF-a have been implicated as having a role.20
Furthermore, Albadawi et al21 have reported that mice with diet-
induced obesity have an exaggerated acute response to hin-
dlimb I/R, with an enhanced metabolic deﬁcit, fat accumulation
and defective functional recovery during the regenerative phase
of I/R. However, it is not currently known whether the detri-
mental effects of lower limb ischemia on the brain are exacer-
bated if diabetes is also present, and if so, which mechanisms
contribute to this phenomenon.
The aim of this study was to investigate whether limb I/R
can cause cerebral injury in a rat model of diabetes and to
explore the potential mechanisms that may be involved with
a focus on GSK-3b signaling.
METHODS
Animals and Grouping
Fifty male Sprague-Dawley rats, weighing 300 to 350 g,
were obtained from the Experimental Animal Center of Guang-
dong Province, China. All rats were housed under speciﬁc
pathogen-free conditions in the Medical Laboratory Animal
Center, Guangzhou University of Traditional Chinese Medicine,
Guangdong, China. The animals were kept in a quiet environ-
ment with a 12:12 hour light-dark cycle, under temperature-
(21–24°C) and humidity- (40%–70%) controlled conditions.
The rats were divided randomly into 2 groups: a T1DM
group (n 5 30) and a control group (n 5 20). The rats in the
T1DM group were divided randomly into 3 subgroups (n 5 10
for each): a sham group, an I/R group and an I/R + TDZD-8
group, whereas rats in the control group were divided randomly
into 2 subgroups (n 5 10 for each): a sham group and an I/R
group. Rats in the T1DM group were treated with STZ to
induce diabetes, whereas rats in the control group were not
treated with STZ. Animals in the I/R groups (both control
and T1DM) were exposed to surgery (limb I/R model) to induce
experimental I/R, whereas animals in the I/R + TDZD-8 group
were injected intravenously with 4-benzyl-2-methyl-1,2,4-
thiadiazolidine-3,5-dione (TDZD-8; a selective GSK-3b inhib-
itor) 5 minutes before the surgery. A sham operation was
performed in the sham group of rats.
Establishment of a Murine Model of T1DM
All rats were acclimatized to their environment for 1
week before any experiments were undertaken. The health
condition of the rats was monitored before treatment with STZ
was initiated, and only rats maintaining a normal diet, no body
weight loss and a normal blood glucose level for 1 week were
used for establishment of the murine model of T1DM.
During the 1st week of the experimental procedure, the
rats in the T1DM and control groups were fasted for 12 hours
and their body weights recorded; the T1DM group animals
were then given a single intraperitoneal injection of 1% STZ
(30 mg/kg; Sigma, Sigma-Aldrich, St. Louis, MO) diluted in
sodium citrate–hydrochloric acid buffer solution (pH 5 4.5;
Sigma), whereas the control group received the vehicle, sodium
citrate–hydrochloric acid buffer solution (pH 5 4.5; 3 mL/kg;
Sigma). One week later, animals in the T1DM group were
given a single intraperitoneal injection of 1% STZ (50 mg/
kg), whereas the control group received the vehicle, sodium
citrate–hydrochloric acid buffer solution (pH 5 4.5; 5 mL/kg).
Blood Glucose Measurements and Criteria for
Successful Establishment of the T1DM Model
Blood glucose levels were measured using a blood
glucose monitor (Onetouch Ultra blood glucose meter;
Johnson, TN) from blood obtained by tail nicking on day 3,
week 1, week 2 and week 3 after the 2nd injection of STZ or
buffer. Water intake, food intake, urine volume and body
weight were monitored. Hyperglycemia was deﬁned as a blood
glucose level $16.7 mmol/L.
Limb I/R Model
Before surgery, the rats were fasted for 12 hours with
free access to water. The animals were anesthetized with
chloral hydrate (3 mL/kg, intraperitoneal). For rats in the I/R
group, the femoral artery and vein were 1st exposed and
ligated for 3 hours; the vascular clamps were then removed to
restore the limb blood supply. A similar surgical procedure
was used for rats in the sham group except that the vasculature
was not ligated.
Therapy
Rats in the I/R + TDZD-8 group were injected intrave-
nously with TDZD-8 (1 mg/kg, dissolved in 10% DMSO, 1
mg/mL) 5 minutes before the I/R surgery was performed; rats in
the other groups received intravenous injection of 10% DMSO
solution (1 mL/kg).
Histological Examination
Rats were deeply anesthetized with an intraperitoneal
injection of 10% chloral hydrate (3 mL/kg) 4 hours after the
limb I/R event. A median sternotomy was performed, blood
collected from the right ventricle and the aorta was perfused
with 400 mL heparinized saline, followed by cold 4% para-
formaldehyde. Whole brains were carefully removed and sliced
coronally at 30-mm intervals beginning at 23.6 mm from the
Bregma. Sections were prepared for hematoxylin and eosin
(H&E) staining, immunohistochemistry for Iba 1 and cleaved-
caspase-3 and the TUNEL assay. The hippocampal CA1 re-
gions were separated on wet ice snap-frozen in liquid nitrogen
and stored at 280°C until enzyme-linked immunosorbent assay
(ELISA) and Western blotting analysis.
H&E Staining
After tissue ﬁxation, 3-mm tissue sections were obtained.
The sections were stained with H&E using standard procedures
and examined under the light microscope.
TUNEL Assay of Hippocampal Cell Apoptosis
The ﬁxed tissues were embedded in parafﬁn and 3-mm
tissue sections obtained. The sections were processed for the
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay according to the manufacturer’s protocol
(Roche, Basel, Switzerland) using an in situ cell death detection
ﬂuorescein kit. In brief, the sections were incubated with the
TUNEL reaction mixture in a humidiﬁed atmosphere for 60 mi-
nutes at 37°C in the dark and then washed 3 times with
phosphate-buffered saline.
Each hippocampal section was 1st examined for cell
apoptosis (magniﬁcation, 1003) and then 3 nonredundant
views were selected (magniﬁcation, 2003) for the counting
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of positively staining cells and total cell number; the percentage
of positively staining cells was then calculated. The average
value for the percentage of positively staining cells was taken
to represent the level of cell apoptosis. The apoptotic cells
showed volume reduction, chromatin condensation and frag-
mentation to form apoptotic bodies.
Immunohistochemistry for Cleaved Caspsase-3 and
Ionized Calcium-Binding Adapter Molecule 1
The hippocampal sections (3 mm thick) were stained
with either rabbit anti-rat ionized calcium-binding adapter mol-
ecule 1 (Iba1) polyclonal antibody (Wako Pure Chemicals
Industries, Ltd, Osaka, Japan) or rabbit anti-rat cleaved
caspase-3 polyclonal antibody (Cell Signaling Technology,
Danvers, MA). The sections were then incubated with goat
anti-rabbit secondary antibody (BIOSS Company, Beijing,
China). The staining of each hippocampal section was 1st
examined at 1003 magniﬁcation and then 3 nonredundant
views were selected for further inspection at 2003 magniﬁca-
tion to count the number of positively staining cells and the
total cell number; the percentage of positively staining cells was
then calculated. The average value for the percentage of posi-
tively staining cells was taken to represent the expression level
of cleaved caspase-3 or Iba1.
Immunoblotting
To determine the levels of GSK-3b, phosphorylated
GSK-3b (p-GSK-3b), NF-kBp65 and phosphorylated NF-
kBp65 (p-NF-kBp65) in the cortex and hippocampus, 50 mg
of rat brain tissue was lysed in 500 mL of lysis buffer and
incubated with rabbit anti-p-GSK-3b (1:1,000), mouse anti-
GSK-3b (1:1,000), rabbit anti-p-NF-kBp65 (1:500) or mouse
anti-NF-kBp65 (1:500) (all from Cell Signaling Technology).
ELISA Assay of TNF-a and IL-6 Levels
Each hippocampal tissue sample was accurately
weighed, and 9 times the volume (ie, 9 mL per 1 g) of
homogenization medium (0.9% saline) was added. Of note,
10% tissue homogenates were prepared mechanically and
centrifuged at 10,000 rpm for 15 minutes at 4°C. The protein
concentration of the supernatant from each sample was deter-
mined using a bicinchoninic acid protein assay kit (Enjing Bio-
tech Ltd, Nanjing, China). The TNF-a levels were assayed
using a TNF-a ELISA kit (Shanghai ExCell Bio Inc, Shanghai,
China). The IL-6 levels were assayed in hippocampal tissue and
rat serum using an IL-6 ELISA kit (Shanghai ExCell Bio Inc).
Statistical Analysis
All data were analyzed using SPSS statistical software
version 18.0 (SPSS Inc, Chicago, IL) for Windows. Comparisons
of TUNEL staining and immunohistochemical staining for
cleaved caspase-3 and Iba1 were made using nonparametric tests;
the Kruskal–Wallis H test was used to assess for differences
between the experimental groups and the Mann-Whitney’s U test
for pairwise comparisons. One-way analysis of variance and Bon-
ferroni correction was used for comparisons between the different
groups in the results of the immunoblot and ELISA experiments.
P , 0.05 was considered to be statistically signiﬁcant.
RESULTS
Establishment of a Rat Diabetes Model
At the end of the 3-week experimental period, none of
the animals had died. A murine model of diabetes was
successfully established in all 30 rats in the T1DM group:
after the establishment of diabetes, blood glucose levels in the
T1DM group were signiﬁcantly higher than those in the
control group (P , 0.05 at 3 days, 1 week, 2 weeks and 3
weeks after I/R surgery; Table 1). Furthermore, within each
of the T1DM and control groups, there were no signiﬁcant
differences in the blood glucose levels between weeks 1, 2
and 3 post-I/R surgery. Rats in the control group exhibited
a moderate increase in body size (as would be expected for
rats of this age), a smooth and glossy coat and no abnormal-
ities in mental state, responsiveness or agility. In contrast, rats
in the T1DM group showed signs of emaciation, a distended
abdomen, slow responsiveness, bradykinesia, mental fatigue,
dulling of their coat, fur loss, increased water and food intake
and increased urine volume and odor. There was no signiﬁ-
cant difference in rat body weight between the T1DM and
control groups before the establishment of diabetes; however,
after the induction of diabetes, rats in the T1DM group had
a signiﬁcantly lower body weight (P , 0.05) than those in the
control group (Table 1).
Diabetes Exacerbates the Brain Injury Induced by
Limb I/R
The results of the H&E staining experiments
(Figure 1A) suggested that the brain injury induced by I/R
was worse in rats in the T1DM group than in those in the
control group. I/R surgery in control rats (control-I/R group)
induced swelling of most of the pyramidal cells of the brain
cortex with decreases in the cytoplasmic and nuclear densities;
some of the neurons showed loss of the nucleolus. Obvious
lesions were evident in the hippocampal CA1 region with
karyopyknosis, deep staining and the appearance of an edem-
atous ﬁssure around the cell. In the diabetes-sham group, there
was shrinkage and deep staining of some of the cortical pyra-
midal cells and some of the neurons in the hippocampal CA1
region, with the appearance of a surrounding edematous












Body weight (g) Control 311.6 6 9.9 341.8 6 10.7 371.4 6 9.4 402.8 6 9.8 432.8 6 9.0
T1DM 309.9 6 13.1 337.5 6 11.7 319.3 6 11.9a 304.0 6 12.5a 289.4 6 12.4a
Blood glucose
(mmol/L)
Control 5.5 6 0.5 5.6 6 0.5 5.6 6 0.4 5.4 6 0.5 5.4 6 0.4
T1DM 6.9 6 0.7 22.7 6 3.4a 24.2 6 3.1a 24.0 6 3.5a 25.0 6 3.2a
Data are presented as mean 6 standard deviation.
a P , 0.05 versus the control group.
I/R, ischemia/reperfusion; STZ, streptozotocin; T1DM, type I diabetes mellitus.
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ﬁssure. Compared with the other groups, rats in the T1DM
group exposed to I/R surgery showed an exacerbation of the
lesions in the brain cortex, a degeneration of the hippocampal
CA1 region and an increase in the number of deep-staining
neurons (Figure 1A). Interestingly, the DM-I/R + TDZD-8
group (ie, rats treated with the GSK-3b inhibitor, TDZD-8)
showed reduced degeneration of the brain cortex and hippo-
campal CA1 region and less pronounced neuronal staining
compared with the DM-I/R group (Figure 1A).
The TUNEL assay revealed very few apoptotic cells in
the control-sham group; in contrast, the proportion of apoptotic
cells was signiﬁcantly increased in the T1DM-sham, control-I/R
and T1DM-I/R groups (P , 0.05) with the T1DM-I/R group
exhibiting a signiﬁcantly larger increase than the other groups
(P , 0.05) (Figures 1B and 1E). In addition, the T1DM-I/R +
TDZD-8 group had a signiﬁcantly smaller percentage of apo-
ptotic cells than the T1DM-I/R group (Figures 1B and 1E).
Immunohistochemistry demonstrated that the T1DM-
sham, control-I/R and T1DM-I/R groups had signiﬁcantly
more cells positive for cleaved caspase-3 (Figures 1C and 1F)
and Iba1 (Figures 1D and 1G) than the control-sham group
(P , 0.05); the largest increases (for both cleaved caspase-3
and Iba1) occurred in the T1DM-I/R group (P , 0.05).
Furthermore, TDZD-8 treatment signiﬁcantly reduced the
FIGURE 1. Cerebral injury induced by hindlimb ischemia–reperfusion is aggravated by diabetes. (A) Representative images of brain
tissue from the hippocampal CA1 area taken from rats in the control-sham, control-I/R, T1DM-sham, T1DM-I/R and DM-I/R+TDZD-8
groups, showing (A) H&E staining, (B) TUNEL staining, (C) immunohistochemical staining of cleaved caspase-3 and (D) immunohis-
tochemical staining of Iba1 (magnification, 2003). (E–G) Quantitative analysis of the data shown in (B–D), respectively. *P, 0.05 versus
the control-sham group; #P , 0.05 versus the DM-I/R group.
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proportion of cells positive for cleaved caspase-3 (Figures 1C
and 1F) or Iba1 (Figures 1D and 1G) compared with the
T1DM-I/R group (P , 0.05).
GSK-3b/NF-kB/TNF-a Signaling Pathway Is
Involved in the Process of Brain Cell Apoptosis
The results of the immunoblotting assay (Figure 2)
showed that the expression of p-GSK-3b and p-NF-kBp65
proteins were signiﬁcantly lower in the control-I/R, T1DM-
sham and T1DM-I/R groups than in the control-sham group
(P , 0.05); however, the expression of GSK-3b and NF-
kBp65 did not differ signiﬁcantly. The decreased expression
of p-GSK-3b and p-NF-kBp65 were most pronounced in the
T1DM-I/R group (P , 0.05). Furthermore, treatment with
TDZD-8 signiﬁcantly increased the expression of p-GSK-3b
(P , 0.05) but signiﬁcantly decreased the expression of
p-NF-kBp65 (P , 0.05).
As presented in Table 2, the TNF-a levels in both the
serum and brain tissue were signiﬁcantly higher in the T1DM-
sham, control-I/R and T1DM-I/R groups than in the control-
sham group (P , 0.05), with the T1DM-I/R group showing
the greatest increase (P , 0.05). Moreover, TDZD-8 signiﬁ-
cantly reduced the production of TNF-a (Table 2). The IL-6
levels as a measure of inﬂammation showed a similar pattern
to the TNF-a with signiﬁcantly higher levels in the T1DM-
sham, control-I/R and T1DM-I/R groups than in the control-
sham group (P , 0.05) and the T1DM-I/R group showing the
greatest increase (P , 0.05). TDZD-8 also signiﬁcantly
reduced the production of IL-6 (Table 3).
DISCUSSION
The main ﬁndings of this study were that cortical and
hippocampal injury, cellular apoptosis, cleaved caspase-3
expression and Iba1 expression were more pronounced in the
T1DM-I/R group than in the control-I/R group and that
TDZD-8 reduced the extent of the injury/apoptosis and
cleaved caspase-3/Iba1 expressions. Moreover, the expres-
sion of p-GSK-3b and p-NF-kBp65 were lower in the
T1DM-I/R group than in the control-I/R group, whereas
TDZD-8 increased p-GSK-3b expression and decreased
p-NF-kBp65 expression. Furthermore, serum and brain
tissue TNF-a levels were elevated more substantially in the
T1DM-I/R group than in the control-I/R group, whereas
TDZD-8 reduced TNF-a production. Taken together, data
indicate that diabetes can exacerbate the cerebral damage
caused by limb I/R and that this may involve a mechanism
recruiting GSK-3b, NF-kB and TNF-a.
The results demonstrated that limb I/R was associated
with injury and apoptosis in the hippocampal CA1 region and
in cortical areas, and that this was aggravated by diabetes.
There is now substantial evidence that I/R injury comprises
a series of inﬂammatory responses, induced by hypoxia of the
ischemic limb and subsequent reperfusion, which can result in
both local and remote damage.22 Although various remote
organs, including the heart, brain, liver, lungs, kidneys and
gastrointestinal tract, are potentially susceptible to injury,7 it is
well known that pyramidal cells in the hippocampal CA1
region are particularly vulnerable to ischemia23 and hence
may also be more prone to secondary injury from limb I/R.
For this reason, the CA1 region in the hippocampus likely
represents an important area of the brain that can be easily
injured after I/R.
GSK-3b is an important protein that is modulated by the
insulin-signaling transduction pathway. Insulin signaling can
inactivate GSK-3b through the PI3K/Akt pathway; hence, the
low-insulin levels associated with diabetes can result in a reduc-
tion in the level of GSK-3b phosphorylation and enhanced
GSK-3b activation.24–26 In this study, the authors found a rela-
tionship between GSK-3b signaling and I/R injury and
observed notable effects of TDZD-8, a non-ATP competitive
GSK-3b inhibitor that increases GSK-3b phosphorylation.20
They found that treatment with TDZD-8 enhanced the phos-
phorylation of GSK-3b; decreased NF-kB activation, micro-
glial cell activation, TNF-a expression in serum and
hippocampal tissue, the number of cleaved caspase-3 positive
cells and neuronal cell apoptosis and ameliorated I/R injury.
Taken together, these results indicate that phosphorylation of
GSK-3b may participate in the mechanisms by which diabetes
exacerbates I/R injury.
There are many factors involved in inﬂammatory re-
sponses. NF-kB is an important component of inﬂammatory
FIGURE 2. Phosphorylation of
GSK-3b and NF-kB is associated
with the cerebral injury induced
by hindlimb ischemia–reperfusion.
(A) GSK-3b and p-GSK-3b lev-
els, detected using immuno-
blotting, in the control-sham
(C-S), control-I/R (C-I), T1DM-
Sham (D-S), T1DM-I/R (D-I) and
T1DM-I/R + TDZD-8 (D-I + T)
groups. (B) Quantitative analysis
of the GSK-3b and p-GSK-3b
levels. (C) NF-kB and p-NF-kB
levels, detected using immuno-
blotting, in the control-sham
(C-S), control-I/R (C-I), T1DM-
Sham (D-S), T1DM-I/R (D-I) and
T1DM-I/R + TDZD-8 (D-I + T)
groups. (D) Quantitative analy-
sis of the NF-kB and p-NF-kB
levels. *P , 0.05 versus the
Control-sham group; #P , 0.05
versus the DM-L I/R group.
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pathways and can initiate the production of various inﬂamma-
tory mediators and function in cascade ampliﬁcation. For this
reason, the NF-kB–related pathway is considered to be a “con-
trol center” and the critical initiating step in the inﬂammatory
response.27,28 Lin et al29 reported that I/R injury could phos-
phorylate NF-kBp65 to activate it. The involvement of
NF-kB/TNF-a pathway is well-established in cerebral I/R
injury.30,31 NF-kB is one of the most important transcription
factors activated after cerebral ischemia. NF-kB is involved in
inﬂammatory responses that potentiate ischemic injury acti-
vating many genes involved in the pathogenesis of cerebral
ischemia, such as iNOS, IL-1b, TNF-a, ICAM-1, COX-2 and
IL-6.32 This study found that limb I/R did not inﬂuence the
expression of NF-kBp65 protein but increased the hippocam-
pal levels of phosphorylated NF-kBp65 indicating signiﬁcant
activation of NF-kB in this brain region. Sustained NF-kBp65
activation would induce a substantial production of proinﬂam-
matory cytokines resulting in an exacerbation of brain injury.
TNF-a can be secreted by vascular endothelial cells,
astrocytes and microglial cells in the central nervous system.33
It is a proinﬂammatory cytokine that can be produced during
the early stages of I/R and can exert a variety of biological
effects including the activation of many cascade reactions.34,35
The 2 possible sources of TNF-a after limb I/R are the affected
limb itself or the microglial cells in the central nervous system.
Despite the blood–brain barrier, cytokines can still enter the
central nervous system through passive diffusion into the cir-
cumventricular organ, which lacks a blood–brain barrier or
through active transport.36,37 In addition, microglial cells and
inﬁltrating immune cells in the brain can also secret cyto-
kines.38,39 This study found low TNF-a expression in the serum
and brain tissue of control rats but signiﬁcant increases in
TNF-a levels in the serum and brain tissue after I/R indicating
substantial activation of proinﬂammatory cytokine secretion.
Furthermore, diabetes enhanced the elevation in TNF-a levels
after I/R suggesting that diabetes can exacerbate the inﬂamma-
tory responses induced by I/R. The authors also found a similar
pattern with IL-6 levels supporting the role of inﬂammation in
this study, but the role and expression patterns of other inﬂam-
matory indices and the role of treatment on inﬂammation will
require further research.
Iba1 is a calcium-binding protein that can speciﬁcally
bind to macrophages and microglial cells. An in vivo and ex
vivo study has conﬁrmed that only microglial cells express Iba1
in brain tissues.40 Iba1 is often used as a marker of microglial
activation because activation of these cells during brain inﬂam-
mation and injury is associated with enhanced expression of
Iba1. In this study, the expression of Iba1 in control rats was
low but increased notably after I/R indicating the enhanced
activation of microglial cells.
A limitation of this study, shared by other investigations
using animal models, is that the existing model cannot be
expected to exactly imitate the clinical pathology that would be
observed in human patients. There are 3 main methods for
modeling I/R injury: the tourniquet model,41 the vascular
clipping model42 and the McGivney hemorrhoidal ligator and
orthodontic rubber ring model.43 This study used the vascular
clipping model with the use of a tension band to block the col-
lateral circulation. Furthermore, this model of streptozotocin-
induced diabetes may not be representative of the mechanisms
underlying diabetes in patients. There are many different rat
models available for investigating the effects of diabetes each
of which have different advantages or disadvantages.44 The
authors used a traditional STZ-induced diabetes model but
made modiﬁcations to establish the model in all of the rats
without any resulting deaths. They used this as a straightforward
model of diabetes establishment but whether this is truly rep-
resentative of diabetes needs to be established in detail; other
more established methods may have been better suited to this
study. They also did not separate the cytoplasmic and nuclear
cell fractions during the protein expression analysis; so, they
cannot say whether transcription factors are binding to pro-
moters; as required by these signaling pathways, the details of
these mechanisms will have to be revealed in later studies.
Nonetheless, this study provides important novel data implicat-
ing GSK-3b signaling in the mechanisms by which diabetes
aggravates cerebral injury after lower limb I/R.
CONCLUSIONS
Limb I/R in this rat model can lead to cerebral damage.
Furthermore, this brain injury is exacerbated by STZ-induced
TABLE 2. TNF-a levels in the brain tissues and sera of rats in the various experimental groups
Control-sham Control-I/R DM-Sham DM-I/R DM-I/R + TDZD-8
Brain tissue TNF-a (pg/mg protein) 4.95 6 2.03 49.10 6 6.49a 30.33 6 4.40a 64.24 6 4.84a 12.18 6 3.70b
Serum TNF-a (pg/mL) 6.11 6 2.97 22.68 6 6.09a 14.57 6 4.74a 38.83 6 4.12a 21.41 6 6.21b
Data are presented as mean 6 standard deviation.
a P , 0.05 versus the control-sham group.
b P , 0.05 versus the DM-I/R group.
DM, diabetes mellitus; I/R, ischemia/reperfusion; TNF-a, tumor necrosis factor alpha.
TABLE 3. IL-6 levels in the brain tissues and sera of rats in the various experimental groups
Control-sham Control-I/R DM-Sham DM-I/R DM-I/R + TDZD-8
Brain tissue IL-6 (pg/mg protein) 5.44 6 1.83 55.57 6 8.38a 43.52 6 7.69a 77.54 6 9.41a 23.57 6 8.41b
Serum IL-6 (pg/mL) 28.86 6 7.25 50.44 6 5.30a 40.55 6 4.60a 59.77 6 7.06a 37.02 6 5.91b
Data are presented as mean 6 standard deviation.
a P , 0.05 versus the control-sham group.
b P , 0.05 versus the DM-I/R group.
DM, diabetes mellitus; I/R, ischemia/reperfusion; IL-6, interleukin 6.
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diabetes mellitus through a mechanism likely to involve
activation of GSK-3b.
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